Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes
Journal of Experimental Medicine · 07.04.2025 · 222 (4)
DOI: 10.1084/jem.20241571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 06.02.2025. Verfasst von Andrew W Simonson und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: BCG Vaccine, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Tuberculosis. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Nonhuman Primate Reagent Resource.
Abstract (Originalsprache)
Tuberculosis (TB) is a major health burden worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the BCG route and dose from 5 × 105 CFUs ID to 5 × 107 CFUs i.v. resulted in prevention of Mycobacterium tuberculosis (Mtb) infection and TB disease in highly susceptible nonhuman primates. Identifying immune mechanisms protection following i.v. BCG will facilitate development of more effective vaccines against TB. Here, we depleted lymphocyte subsets prior to and during Mtb challenge in i.v. BCG–vaccinated macaques to identify those necessary for protection. Depletion of adaptive CD4 T cells, but not adaptive CD8αβ T cells, resulted in loss of protection with increased Mtb burdens and dissemination, indicating that CD4 T cells are critical to i.v. BCG–mediated protection. Depletion of unconventional CD8α-expressing lymphocytes (NK cells, innate T cells, and CD4+CD8α+ double-positive T cells) abrogated protection in most i.v. BCG–immunized macaques, supporting further investigation into which of these cell subsets contribute to protection after vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Center for Vaccine Research, University of Pittsburgh School of Medicine , Pittsburgh, PA, USA.
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) , Bethesda, MD, USA.
- Ragon Institute of MGH, MIT, and Harvard , Cambridge, MA, USA.
- Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Division of Animal Laboratory Resources, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
ORCID-Profile: Andrew W Simonson, Joseph J Zeppa, Allison N Bucsan, Michael C Chao, Supriya Pokkali, Forrest Hopkins, Michael R Chase, Andrew J Vickers, Matthew S Sutton, Caylin G Winchell, Amy J Myers, Cassaundra L Ameel, Ryan J Kelly, Ben Krouse, Luke E Hood, Jiaxiang Li, Chelsea C Lehman, Megha Kamath, Jaime Tomko, Mark A Rodgers, Rachel Donlan, Harris Chishti, H Jacob Borish, Edwin Klein, Charles A Scanga, Sarah M Fortune, Philana Ling Lin, Pauline Maiello, Mario Roederer, Patricia A Darrah, Robert A Seder, JoAnne L Flynn
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Nonhuman Primate Reagent Resource
- NIH HHS
- Bill and Melinda Gates Foundation
- National Institutes of Health
Zitieren
APA
Simonson, A. W., Zeppa, J. J., Bucsan, A. N., Chao, M. C., Pokkali, S., Hopkins, F., Chase, M. R., Vickers, A. J., Sutton, M. S., Winchell, C. G., Myers, A. J., Ameel, C. L., Kelly, R. J., Krouse, B., Hood, L. E., Li, J., Lehman, C. C., Kamath, M., Tomko, J., …, & Flynn, J. L. (2025). Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes. Journal of Experimental Medicine, 222(4). https://doi.org/10.1084/jem.20241571
Vancouver
Simonson AW, Zeppa JJ, Bucsan AN, Chao MC, Pokkali S, Hopkins F, et al. Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes. Journal of Experimental Medicine. 2025;222(4). doi:10.1084/jem.20241571
BibTeX
@article{Simonson2025,
author = {Simonson, Andrew W and Zeppa, Joseph J and Bucsan, Allison N and Chao, Michael C and Pokkali, Supriya and Hopkins, Forrest and Chase, Michael R and Vickers, Andrew J and Sutton, Matthew S and Winchell, Caylin G and Myers, Amy J and Ameel, Cassaundra L and Kelly, Ryan J and Krouse, Ben and Hood, Luke E and Li, Jiaxiang and Lehman, Chelsea C and Kamath, Megha and Tomko, Jaime and Rodgers, Mark A and Donlan, Rachel and Chishti, Harris and Borish, H Jacob and Klein, Edwin and Scanga, Charles A and Fortune, Sarah M and Lin, Philana Ling and Maiello, Pauline and Roederer, Mario and Darrah, Patricia A and Seder, Robert A and Flynn, JoAnne L},
title = {Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes},
journal = {Journal of Experimental Medicine},
year = {2025},
volume = {222},
number = {4},
doi = {10.1084/jem.20241571}
}
EUVIMED